MeiraGTx Holdings plc (MGTX) Stock Price & Analysis

MeiraGTx Holdings plc (MGTX) is trading at USD 9.78, up 0.26% today, as of October 29, 2026 at 16:06 UTC (US market open; quotes may be delayed), according to Nexqual market data.

MGTX last closed at USD 9.75; today's session has ranged USD 9.58–9.9 on volume of 100,293 shares. Market capitalization is $938.82M, with a 52-week range of USD 6.62–15.35 (NMS). Source: Nexqual, retrieved October 29, 2026 at 16:07 UTC.

Also available as compact Markdown for AI agents: nexqual.com/MGTX.md

Key facts (MGTX)

• Last four reported quarters (through Jun 30, 2026): revenue $398M, net income $79.0M (19.9% margin), free cash flow $10.5M (SEC filings).
• Valuation: P/E 11.9x, EV/EBITDA 4.6x, net cash $43.2M.
• Insider open-market sales, last ~7 months: 7 Form 4 filings, $4.0M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.88 on a 1–5 scale) (8 analysts), mean target USD 27.75 (range 16–50).
• Total return with dividends: 1Y +9.5% vs S&P 500 +13.2%; 5Y -54.5% vs S&P 500 +79.2%.
• Next earnings: 2026-11-12, EPS estimate USD -0.47, revenue estimate $7.0M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MGTX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (MGTX)

P/E 11.9x · P/S 2.4x · EV/EBITDA 4.6x · EV/Sales 2.3x · P/FCF 89.7x · P/B 4.3x · FCF yield 1.11% · Earnings yield 8.41% · Net cash $43.2M · EV $896M

Insider sales (SEC Form 4, open-market, last ~7 months) (MGTX)

7 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (MGTX)

Consensus Buy (mean 1.88 on a 1–5 scale), 8 analysts; mean target USD 27.75 (low 16, high 50).

Rating changes, last 120 days:

Total return (dividends reinvested) (MGTX)

MGTX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

MGTX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

MGTX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 30, 2026.

Companies that name MGTX in their SEC reports

MGTX analyst estimates and revisions

MGTX options: expected move

Options price a move of about ±50.3% (±$4.80) by Nov 20, 2026, which includes earnings on Nov 12, 2026. Over the last 8 reports the stock moved ±7.1% on average.

30-day implied volatility 95% vs 53.3% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 16:07 UTC)

Technical Analysis (MGTX)

Nexqual's technical model rates MGTX "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of October 29, 2026 at 16:07 UTC.

Analyst Ratings (MGTX)

Wall Street analysts rate MGTX "Buy" based on 8 analysts, with a mean price target of USD 27.75 (range USD 16–50), per Nexqual as of October 29, 2026 at 16:07 UTC.

Earnings (MGTX)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 16:07 UTC.

Financials & Fundamentals (MGTX)

Source: Nexqual, October 29, 2026 at 16:07 UTC.

Financial Health Score (MGTX)

Nexqual rates MeiraGTx Holdings plc's overall financial health "Strong" across five dimensions, as of October 29, 2026 at 16:07 UTC.

Ownership (MGTX)

Source: Nexqual, October 29, 2026 at 16:07 UTC.

Leadership (MGTX)

MeiraGTx Holdings plc is led by Alexandria Forbes, CEO, President & Director, per Nexqual as of October 29, 2026 at 16:07 UTC.

Major Backers & Investors (MGTX)

Notable institutional backers of MeiraGTx Holdings plc include Sanofi, Perceptive Advisors Llc, Rubric Capital Management LP, according to Nexqual as of October 29, 2026 at 16:07 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 16:07 UTC.

From MeiraGTx Holdings plc's Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• We are a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including radiation-induced xerostomia, Parkinson's disease and AIPL1-associated retinal dystrophy.
• During 2024, we gained alignment with the FDA on requirements for the Phase 2 AQUAx2 clinical trial to be considered a pivotal trial in support of a potential Biologics License Application, or BLA, filing.
• The successful development of the clinical pipeline is supported by our internal end-to-end manufacturing capabilities.
• Lilly also has a right of first negotiation for use of our proprietary riboswitch technology in the field of ophthalmological gene editing.

Partnerships

• We entered into a strategic collaboration with Lilly in the area of ophthalmology, including granting Lilly worldwide exclusive rights to our AAV-AIPL1 program for the treatment of patients with Leber congenital amaurosis 4, or LCA4, caused by mutations in the AIPL1 gene.
• On November 7, 2025 (the "Effective Date"), our affiliates MeiraGTx Ocular UK Limited ("MeiraGTx Ocular"), MeiraGTx Limited and MeiraGTx UK II Limited, entered into a strategic collaboration and license agreement with Eli Lilly and Company ("Lilly") (the "Lilly Collaboration Agreement") for the research, development and commercialization of genetic medicines in and related to the area of ophthalmology.

Legal & Regulatory Risks (Item 1A, quoted)

• We may not have sufficient cash flows or cash on hand to satisfy our debt obligations or covenants under our financing arrangements, or we may not be able to effectively manage our business in compliance with such covenants.
• We are heavily dependent on the success of our product candidates, which are still in development, and if none of them receive regulatory approval or are successfully commercialized, our business may be harmed.
• Risks Related to Discovery, Development, Clinical Testing, Manufacturing and Regulatory Approval
• We and our contract manufacturers for plasmid are subject to significant regulation with respect to manufacturing our products. Our manufacturing facilities and the third-party manufacturing facilities which we rely on may not continue to meet regulatory requirements and have limited capacity.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 16:07 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt